anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Budesonide, the active ingredient of budesonide delayed-release capsules, is a synthetic corticosteroid. Budesonide is designated chemically as (RS)-11β, 16α, 17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde. Budesonide is provided as a mixture of two epimers (22R and 22S). The empirical formula of budesonide is C25H34O6 and its molecular weight is 430.5. Its structural formula is:

Budesonide is a white to off-white, tasteless, odorless powder that is practically insoluble in water and heptane, sparingly soluble in ethanol, and freely soluble in chloroform. Its partition coefficient between octanol and water at pH 5 is 1.6 x 103 ionic strength 0.01.

Budesonide delayed-release capsules are formulated as hard gelatin capsules filled with enteric-coated granules that dissolve at pH greater than 5.5. Each capsule for oral administration contains 3 mg of micronized budesonide with the following inactive ingredients: ethylcellulose, acetyltributyl citrate, methacrylic acid copolymer type C, triethyl citrate, antifoam M, polysorbate 80, talc, and sugar spheres. The capsule shells have the following inactive ingredients: gelatin, iron oxide, and titanium dioxide.
The invention relates to the use of an attenuated live strain of Staphylococcus aureus as a vaccine against ruminant mastitis. More specifically, the invention relates to a novel live vaccine strain of S. aureus which, in addition to being attenuated, is characterized by the following more significant innovations, namely: greater proliferation rates and persistence in mammary epithelial cells. The aforementioned properties promote a prolonged immune response. Said strain has been deposited and registered in the Spanish Type Culture Collection (CECT) at the University of Valencia, Campus de Burjassot, Edificio de Investigación, 46100 Burjassot (Valencia), with reference number CECT 7061.  The strategy used in the construction thereof confers complete genetic stability on the mutation. In addition, the vaccine strain lacks antibiotic resistance markers in order to fulfil the associated biological safety requirement.
Subjects will undergo a single MRI session and will then participate in an on-line neuro-navigation session in which various TMS coil positions will be recorded. The brain/head images will be provided to the programmer to permit development of the virtual neuro-navigation algorithm. Data from Yr1 will be used by the programmer as a training sample, and from Yr2 as a test sample.
The invention provides a way for peoples' health to be monitored as they walk down a hallway or through a door frame by tracking their temperatures and by the individuals periodically stopping to give blood samples. An individual's average temperature and the fluctuations to that temperature can state a lot about their health. Keeping track of this information could potentially allow illnesses to be detected earlier. Through cloud-based software, this information is sent to doctors to later use when determining the progression of an illness of a patient or just to monitor the patient. There would be a monitor and speakers available for the user to be able to interface with the system to access their personal health history and if they are a parent, have access to their children's information.  Facial recognition would provide a quick way to allow the system to store information about the individual's health.
An analyte monitoring system may include an analyte sensor and a transmitter. The analyte sensor may include an indicator element that exhibits one or more detectable properties based on an amount or concentration of an analyte in proximity to the indicator element. The analyte sensor may be configured to generate one or more raw signals indicative of one or more analyte amounts or concentrations. The transmitter may be configured to receive from the analyte sensor one or more raw signals indicative of analyte concentration. The transmitter may be configured to denoise the raw signal using a real-time filtering technique with one or more time-varying parameters. The transmitter may be configured to predict ahead of time an analyte concentration based on one or more of the received one or more raw signals using one or more prediction models.
The invention comprises sulpha-pyrimidines of the formula <FORM:1035917/C2/1> wherein one of R1 and R2 is a lower alkoxy-lower alkyl group and the other is hydrogen, halogen or a lower alkyl, lower alkoxy, lower alkoxy-lower alkyl or lower alkoxy-lower alkoxy group (the word "lower" indicating a group of 1-6 carbon atoms), and Z1 is an amino, nitro, azo or acylamino group, with the exception of 6 - sulphanilamido - 2 - methoxymethyl - 4 - methoxy pyrimidine; salts and N1-acyl derivatives of the sulphanilamides of the above formula; corresponding 6-bis(p-Z-benzenesulphonyl) -amino pyrimidines and processes for the preparation of these compounds by reacting a p-substituted benzenesulphonyl halide with a 4-amino-pyrimidine, or reacting a p-substituted benzenesulphonamide with a 4-halo-pyrimidine or a pyrimidine-4-trialkylammonium compound and, if desired, converting a nitro, azo or acylamino group in a resulting compound into an amino group by reduction or hydrolysis, N1-acylating the product and converting any free compound obtained into a salt or a salt into a free compound.  2 - Lower - alkoxy - lower - alkyl - 4 - R4 - 6 R7 - pyrimidines in which R4 is a hydrogen or halogen atom or a lower alkoxy or lower alkoxy-alkoxy group and R7 is a free hydroxyl, mercapto or amino group or a substituted mercapto, e.g. alkyl mercapto or benzyl mercapto group or a halogen atom, used as starting materials, are made by reacting an amidine of an alkoxy-alkanoic acid with a malonic acid diethyl ester or diacetonitrile and, if desired, converting hydroxyl groups in the 4- and/or 6-position of the resulting pyrimidine into a halogen atom (e.g. with phosphorus oxychloride) and/or a hydroxyl group in the 6-position to a mercapto group and/or a halogen atom in the 6-position into an amino or free or substituted mercapto group and any free mercapto group in the 6-position into a substituted amine group and/or a free or substituted mercapto group into a free amino group and/or a halogen atom in the 4-position into a lower alkoxy or lower alkoxy-alkoxy group or replacing it by hydrogen. Alkoxy-alkanoic-amidines, e.g. methoxy- and ethoxy-acetamidine and methoxy propionamidine are made by treating the appropiate nitrile with ethanolic hydrogen chloride and reacting the resulting imino-ether with ammonia.  Pharmaceutical preparations for the treatment of bacterial infections in man and animals comprise the above compounds of the invention in admixture or conjunction with a pharmaceutically suitable carrier.  The preparations may suitably take the form tablets, dragees, salves, creams, solutions, suspensions or emulsions or animal feedstuff additives.
BACKGROUND: Pervasive symptoms from chronic pancreatitis despite noninvasive management is an indication for surgical intervention. Frey and Whipple procedures are appropriate options for proximal pancreas disease; however, data are limited on symptomatic outcomes.
METHODS: We conducted a retrospective analysis of patients who underwent surgical intervention for chronic pancreatitis of the proximal pancreas from 2005 to 2019. Preoperative patient characteristics and postoperative outcomes were evaluated.
RESULTS: One hundred forty patients underwent surgical intervention for chronic pancreatitis, 91 Whipple and 49 Frey procedures. Mean age was 53 years (SD 12), and mean BMI 24 (SD 5.6). At post-operative follow-up, 74 ​% were asymptomatic, and 84 ​% at average follow-up of 2 years. Groove pancreatitis, lack of post-operative delayed gastric emptying, and decreased length of stay were predictive of symptom resolution.
CONCLUSIONS: Whipple and Frey procedures are appropriate surgical options for chronic pancreatitis affecting the proximal pancreas. Both lead to sustained symptom resolution for most patients.
Breast cancer mortality results from incurable recurrences thought to be seeded by dormant, therapy-refractory residual tumor cells (RTCs). Understanding the mechanisms enabling RTC survival is therefore essential for improving patient outcomes. Here, we derive a dormancy-associated RTC signature that mirrors the transcriptional response to neoadjuvant therapy in patients and is enriched for extracellular matrix-related pathways. In vivo CRISPR-Cas9 screening of dormancy-associated candidate genes identifies the galactosyltransferase B3GALT6 as a functional regulator of RTC fitness. B3GALT6 is required for glycosaminoglycan (GAG) linkage to proteins to generate proteoglycans, and its germline loss of function in patients causes skeletal dysplasias. We find that B3GALT6-mediated biosynthesis of heparan sulfate GAGs predicts poor patient outcomes and promotes tumor recurrence by enhancing dormant RTC survival in multiple contexts, and does so via a B3GALT6-heparan sulfate/HS6ST1-heparan 6-O-sulfation/FGF1-FGFR2 signaling axis. These findings implicate B3GALT6 in cancer and nominate FGFR2 inhibition as a promising approach to eradicate dormant RTCs and prevent recurrence.
A thoracic epidural catheter is placed before induction of general anaesthesia. Sufentanil 10 µg and Ropivacaine are applied via the catheter.
BACKGROUND: Ageing entails changes in complex cognitive functions that lead to a decrease in autonomy and quality of life. Everyday cognition is the ability to solve cognitively complex problems in the everyday world, enabling instrumental activities of life. Benefits have been found in studies using everyday cognition-based assessment and intervention, as the results predict improvements in everyday performance, not just in specific cognitive functions. A study protocol is presented based on assessment and training in everyday cognition versus traditional cognitive stimulation for the improvement of functionality, emotional state, frailty and cognitive function.
METHODS: A parallel randomised controlled clinical trial with two arms will be conducted. It will be carried out by the University of Salamanca (Spain) in eleven centres and associations for the elderly of the City Council of Salamanca. People aged 60 years or older without cognitive impairment will be recruited. Participants will be randomly distributed into two groups: the experimental group will undergo a training programme in everyday cognition and the control group a programme of traditional cognitive stimulation, completing 25 sessions over 7 months. All participants will be assessed at the beginning and at the end of the intervention, where socio-demographic data and the following scales will be collected: The Medical Outcomes Study (MOS), Questionnaire ARMS-e, Everyday Cognition Test (PECC), Scale Yesavage, Test Montreal Cognitive Assessment (MoCA), The Functional Independence Measure (FIM), Fragility Index and Lawton y Brody Scale.
DISCUSSION: The present study aims to improve conventional clinical practice on cognitive function training by proposing a specific assessment and intervention of everyday cognition based on the importance of actual cognitive functioning during the resolution of complex tasks of daily life, giving priority to the improvement of autonomy.
TRIAL REGISTRATION: ClinicalTrials.gov; ID: NCT05688163. Registered on: January 18, 2023.
Participants received an IV injection of ferumoxytol (510 milligrams \[mg\], 17 milliliters \[mL\]) on Day 1 (Baseline). This was followed by a second injection of ferumoxytol (510 mg, 17 mL) 5±3 days later for a total cumulative dose of 1.02 grams (g).
Epstein-Barr Virus (EBV) is associated with numerous cancers including B cell lymphomas. In vitro, EBV transforms primary B cells into immortalized Lymphoblastoid Cell Lines (LCLs) which serves as a model to study the role of viral proteins in EBV malignancies. EBV induced cellular transformation is driven by viral proteins including EBV-Nuclear Antigens (EBNAs). EBNA-LP is important for the transformation of naïve but not memory B cells. While EBNA-LP was thought to promote gene activation by EBNA2, EBNA-LP Knockout (LPKO) virus-infected cells express EBNA2-activated cellular genes efficiently. Therefore, a gap in knowledge exists as to what roles EBNA-LP plays in naïve B cell transformation. We developed a trans-complementation assay wherein transfection with wild-type EBNA-LP rescues the transformation of peripheral blood- and cord blood-derived naïve B cells by LPKO virus. Despite EBNA-LP phosphorylation sites being important in EBNA2 co-activation; neither phospho-mutant nor phospho-mimetic EBNA-LP was defective in rescuing naïve B cell outgrowth. However, we identified conserved leucine-rich motifs in EBNA-LP that were required for transformation of adult naïve and cord blood B cells. Because cellular PPAR-g coactivator (PGC) proteins use leucine-rich motifs to engage transcription factors including YY1, a key regulator of DNA looping and metabolism, we examined the role of EBNA-LP in engaging transcription factors. We found a significant overlap between EBNA-LP and YY1 in ChIP-Seq data. By Cut&Run, YY1 peaks unique to WT compared to LPKO LCLs occur at more highly expressed genes. Moreover, Cas9 knockout of YY1 in primary B cells prior to EBV infection indicated YY1 to be important for EBV-mediated transformation. We confirmed EBNA-LP and YY1 biochemical association in LCLs by endogenous co-immunoprecipitation and found that the EBNA-LP leucine-rich motifs were required for YY1 interaction in LCLs. We propose that EBNA-LP engages YY1 through conserved leucine-rich motifs to promote EBV transformation of naïve B cells.
FIELD: medicine, chemical-pharmaceutical industry. SUBSTANCE: invention relates to methods of preparing wound-healing and antibacterial agents from vegetable raw. Before extraction walnut leaves are wetted in 35-45% ethyl alcohol (1:1) and extraction is carried out three-fold with 35-45% ethyl alcohol by infusion method at total ratio raw : extractant = 1:5. Obtained extracts are combined, infused for 3 days at 6-10 C, filtered and concentrated if necessary to obtain viscous or dried extract. EFFECT: simplified process, decreased time of procedure, increased yield, broadened spectrum of specific activity of end product. 3 cl, 3 ex
The MINIMA-2 Study is a multi-center clinical trial that initiated in order to investigate the effect of microdoses of ranibizumab in diabetic macular edema. The duration of the study is up to 13 months. Patients with diabetic macular edema will be randomized into 2 different groups. Consented subjects will receive monthly injections over a 6-month treatment period, and a 6 month follow-up and treatment period. Several eye examinations and procedures will be performed to evaluate response to the treatment. These include best corrected visual acuity testing (ETDRS), contrast sensitivity testing, ophthalmic examination, fluorescein angiography (FA)and macular thickness measurements based on optical coherence tomography (OCT). Serum chemistry, hematology and glycosylated hemoglobin HbA1c testing, urinalysis and pregnancy testing will be performed at screening visit (Days -14 to 0) and two more times during the study.

Approximately 72 patients with a baseline central foveal thickness by OCT of at least 270 will be included. The BCVA must be worst than 20/40 but better than or equal to 20/320 due diabetic macular edema.
efficacy of mirabegron was evaluated in Study 9 (NCT02751931), a 52-week, open-label, baseline-controlled, multicenter, dose titration study in pediatric patients 3 years of age and older for the treatment of neurogenic detrusor overactivity (NDO). Study 9 included patients 3 to 17 years of age. Entry criteria required that patients had a diagnosis of neurogenic detrusor overactivity (NDO) with involuntary detrusor contractions with detrusor pressure increase greater than 15 cm H2O and that patients or their caregivers practiced clean intermittent catheterization (CIC). Mirabegron were administered orally once daily. All patients initially received a weight-based starting dose equivalent to 25 mg daily dose followed by dose titration to a dose equivalent of 50 mg daily dose. The duration of the dose titration period was up to 8 weeks and this period was followed by a dose maintenance period that continued for the duration of the 52-week study.

In Study 9, a total of 86 patients 3 to 17 years of age received mirabegron. Of these, 71 patients completed treatment through week 24 and 70 completed 52 weeks of treatment. A total of 68 patients (43 patients 3 to less than 12 years of age and 25 patients 12 to 17 years of age) had valid urodynamic measurements for evaluation of efficacy. The study population included 39 males (45%) and 47 females (55%). The optimized maintenance dose within this study population included 94% of patients at the maximum dose, and 6% of patients at the starting dose.

The primary efficacy endpoint was change from baseline in the patients' maximum cystometric (bladder) capacity (MCC) after 24 weeks of treatment with mirabegron. As shown in Table 7, improvements in MCC were observed in patients 3 to less than 12 years of age and in patients 12 to 17 years of age. The magnitude of the observed changes from baseline in the primary and secondary efficacy endpoints were comparable between patients 3 to less than 12 years of age and patients 12 to 17 years of age. 

Table 7: Change from Baseline in Maximum Cystometric Capacity (MCC) at 24 Weeks in Pediatric Patients with Neurogenic Detrusor Overactivity (NDO) Treated with Mirabegron in Study 9

Secondary efficacy endpoints from Study 9 for mirabegron in pediatric patients with neurogenic detrusor overactivity (NDO) are shown below in Table 8 and Table 9.

Table 8: Changes from Baseline in Other Urodynamic Parameters at Week 24 in Pediatric Patients with Neurogenic Detrusor Overactivity (NDO) Treated with Mirabegron in Study 9
The present invention relates to the use of novel antiviral agents for the combination therapy of covd-19 (SARS-CoV-2). The agent comprises a therapeutically effective amount and ratio of Aprotinin (APR) or a pharmaceutical formulation based thereon and an inhibitor of SARS-CoV-2 replication. The aprotinin-based pharmaceutical preparation is preferably selected from Aprotex, vero-Narcap, ingitril, contrykal, contricel, Inhiprol、Aprotimbin、 Contriven, traskolan or aeros. The Fapirrevir (FPV) or Ruidexivir (RMD) or a pharmaceutical formulation based thereon can be used as an inhibitor of SARS-CoV-2 replication. The drug preparation based on the fampicvir is preferably selected from Avigan, favilavir, abamectin, coronavir or Fabiflu. The use of new anti-coronavirus agents produces new and synergistic effects and allows for a significant reduction in the duration of treatment and a reduced risk of adverse side effects.
BACKGROUND: Gynura procumbens, a well-known traditional herb, has been studied to be an effective chemotherapeutic agent against a wide range of cancer cell types.
CASE DESCRIPTION: A 7-year-old chihuahua dog was presented to the veterinary teaching hospital with multiple cutaneous MCT grade III masses found on the cranial aspect of the right front leg and the dorsal aspect of the neck/back. Local excision of all cutaneous tumors was performed followed by chemotherapy (vinblastine, prednisone, and cyclophosphamide) every 21-day interval for 9 treatments. Nearby 3 months later, recurrent MCT was observed and lomustine was used instead for 21-day intervals. During the first chemotherapy, the dog had a fever, weak, lethargy, and vomiting. Alternative natural therapy is preferred, the dog has been receiving G. procumbens daily. The dog responded well to this herbal treatment. These recurrent masses began to shrink after a few weeks of treatment. After several months of treatment, all masses were completely gone. Moreover, no micro-metastasis to the lungs, spleen, and liver were detected.
CONCLUSION: This natural herbal was helpful to stop the growth of tumors, to prevent micro-metastasis, and to relieve the patient's symptoms.
The application discloses a method and a device for judging attributes of medical entities and related products. Firstly, processing a medical record text by using a label generation model to obtain a label string; and then, obtaining the attribute labels of the medical entities in the medical record text according to the attribute labels in the label string and the sequencing of the attribute labels. The attribute tags of the medical entity can be used to discriminate the attributes of the medical entity. The first model in the label generation model dynamically generates the vector of the character according to the actually input medical record text, and the label generation model combines the context information of the character when generating the attribute label of the character, so that the accuracy of the attribute label of the character is improved. The second model is obtained through deep learning method training, and the label string can be generated according to the vector string output by the first model, so that the ordered correspondence between the label attribute in the label string and the characters in the medical history text is ensured. Therefore, compared with the prior art, the accuracy of the medical entity attribute discrimination is improved.
Dendritic cells are cells that are present in your body's immune system that help your body fight disease. This is a vaccine trial, as your own cells will be extracted (removed), treated in a lab, then re-administered to your body with the study drug in hopes of creating an immune response to the disease. It is not guaranteed that your disease burden will be reduced by participating in this trial.TScreening tests will be conducted to determine whether or not subjects can participate in this study. If subjects are eligible and choose to participate, they will have a procedure called leukapheresis. The leukapheresis product that is collected from you will be taken to a special lab at MUSC where it will undergo a process that will grow additional dendritic cells under controlled conditions in the lab. These cells will be given together with Poly-ICLC therapy when you begin study treatment. Some days you will receive both Poly-ICLC and dendritic cells, but on other days you will receive the Poly-ICLC by itself. After study treatment, subjects may be asked to return to MUSC approximately every 3 months for the first 2 years, then every 6 months thereafter for follow up procedures.
Ulcerative colitis (UC) poses a threat to human health. The present study attempts to unravel the efficacy and potential mechanisms of paeoniflorin (PF), a naturally sourced active ingredient, for the management of UC. By establishing a DSS (dextran sulphate sodium)-induced experimental rat model of UC, this study found that PF was effective in ameliorating UC symptoms, inhibiting oxidative stress, inflammation and apoptosis, and repairing colonic epithelial damage. In addition, metabolomics revealed that PF may alleviate UC by primarily improving linoleic acid metabolism. Mechanistically, PF inhibited the CDC42/JNK signaling pathway by targeting CDC42. In particular, HuProtTM20K proteomics, molecular docking and MST revealed that PF is a novel CDC42 inhibitor. In LPS-treated Caco-2 cells, PF similarly inhibited oxidative stress, inflammation, and apoptosis and down-regulated the CDC42/JNK signaling pathway. Overall, PF inhibits oxidative stress, inflammation and apoptosis and repairs colonic epithelial damage through modulation of serum metabolites and inhibition of the CDC42/JNK signaling pathway, leading to alleviation of UC.